The first drug company in more than three decades to try to fight prescription drugs that have no medical benefit for people has filed a patent for a new drug.
It is the first drug to offer a generic form of the drug called a “selective” version of a drug that would not have any medical benefits, which could be important to the future of generic drugs.
This drug would be manufactured by an Australian company, called Synthese, which would be a subsidiary of Anil Ambani, founder of Reliance Industries, and Anil’s father, Gautam.
A new generic version of the generic drug called the “selectively generic” drug.
The patents are being filed with the United States Patent and Trademark Office.
Synthesem said it plans to launch the drug by the end of 2017 and that the new drug could be available within the next year.
The Drug Development and Manufacturing (D&M) Department of the Food and Drug Administration (FDA) said it was working with SyntheSem in the U.S. to ensure that this new generic drug is safe and effective.
The department said it would also be providing financial support to Synthe Sem to continue development of the product.
Synthesem is not the first generic drug company to try this strategy.
In 2012, Amgen announced it was filing a patent application for a drug called Nolva that would have a generic version, but the drug would not be available in the United Kingdom.
Synesem said its drug would also have a lower price.
It said the drug could potentially be available by the first quarter of 2020.
Synesthesia Drug Company, Inc., which is backed by the Anil Group, filed a similar patent application in the Netherlands in February 2016.
A company spokesman said the company plans to file a patent in Australia by the fourth quarter of 2018.